DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Lynch syndrome 2 — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleLynch syndrome 2 maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for lynch syndrome 2 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
mutL homolog 1 (MLH1) — MLH1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet adpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4P7A · 2.3 Å · ligand ADENOSINE-5'-DIPHOSPHATE (ADP). Experimental structure, not a prediction.
What the evidence adds up to
Gastrointestinal biopsies from 18 members of a single family with Lynch Syndrome II were evaluated in 1986. Immunocytochemical studies characterised the phenotypic expression of immune populations in the tissue. The intestinal findings suggested polyclonal B-cell activation related to the T-helper distribution. The authors stated that the evaluation provided no specific information on the management of patients with Lynch Syndrome II.
A 2020 study from the Mater Hospital examined patients categorised as ‘LS Unconfirmed’ in a high-risk database — those meeting clinical criteria (Amsterdam or Bethesda) but without genetic testing. The study questioned whether these patients were being classified correctly and receiving appropriate surveillance. No survival or response rate data were reported.
A 2025 review describes Lynch syndrome as a germline cancer predisposition syndrome caused by a variant in one of four mismatch repair genes. It places individuals at significantly higher risk for colorectal and endometrial cancers, and depending on the gene, for ovarian, gastric, small bowel, pancreatic, biliary, urothelial, brain, and certain skin tumours. The review states that Lynch syndrome remains underdiagnosed, with only a small proportion of those affected aware of their genetic predisposition. It explores the patient journey from awareness and suspicion through diagnosis, treatment, surveillance, and psychosocial adaptation. The authors recommend improvements in healthcare coordination and communication but provide no new trial data or quantitative outcomes.
What is still missing: prospective trials that link immune phenotyping to clinical outcomes in Lynch syndrome II, systematic genetic confirmation for patients meeting clinical criteria, and funded studies that measure whether improved healthcare coordination actually reduces cancer incidence or mortality in this population.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
The International Journal of Biological Markers · 1986 · 1 citations
Lymphocyte Subpopulations in Lynch Syndrome Ii: An Immunocytochemical Study on Gastrointestinal Biopsies. Preliminary Report
AbstractGastrointestinal biopsies from 18 members of a family with Lynch Syndrome II were evaluated and immunocytochemical studies were made to characterize the phenotypic expression of the tissue's immune populations. The intestinal findings suggest polyclonal B-cell activation related to the T-helper distribution. Our evaluation provides no specific information so far on the management of patients with Lynch Syndrome II.
HIGH RISK PATIENTS SUSPICIOUS OF LYNCH SYNDROME; ARE THEY BEING CLASSIFIED CORRECTLY AND RECEIVING APPROPRIATE SURVEILLANCE?
AbstractAims Lynch Syndrome (LS) is diagnosed by genetic testing of mismatch repair genes. However, before genetic testing, patients are categorised by clinical criteria (Amsterdam/Bethesda). The Mater Hospital (MMUH) cohort of patients without genetic testing but meeting the clinical criteria are categorised as ‘LS Unconfirmed’ in the high-risk database and surveillance is arranged accordingly.
International Journal of Cancer · 2025 · 0 citations · open access
Living at genetic risk: The patient experience of Lynch syndrome
AbstractLynch syndrome is a germline cancer predisposition syndrome caused by a variant in one of four genes. Lynch syndrome places individuals at significantly higher risk for a range of cancers, especially colorectal and endometrial. Depending on which gene is affected, the risk of ovarian, gastric, small bowel, pancreatic, biliary urothelial, brain, and certain skin tumors is also increased. Tailored treatment, cancer surveillance, and consideration of primary prevention measures are critical for at-risk individuals. Despite advancements in genetic testing, Lynch syndrome remains underdiagnosed, with only a small proportion of those affected aware of their genetic predisposition. This article explores the patient experience of living with Lynch syndrome, focusing on the challenges surrounding diagnosis, risk-adjusted prevention, healthcare coordination, and information dissemination. Stages of the patient journey are explored, from awareness and suspicion to diagnosis, treatment and surveillance, psychosocial adaptation, and ongoing management. The need for more comprehensive healthcare strategies and better communication to enhance the quality of care for Lynch syndrome patients is emphasized. We recommend improvements to better meet patient needs.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
